Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Vildagliptin delayed

The launched of vildagliptin (Glavus®) has been delayed by a safety update on liver enzyme elevations according to PharmaTimes.

The article states that liver enzyme elevations were less frequent in patients taking 50mg each day or 50mg twice daily compared to those taking 100mg daily. This finding has raised safety concerns and may impact on the use of this drug as a true once-daily medication.

Action: The gliptins are new agents and their place in therapy is where other agents have failed or are not tolerated. Previous recommendations are unchanged.

Share 'Vildagliptin delayed' on Email Share 'Vildagliptin delayed' on Delicious Share 'Vildagliptin delayed' on Digg Share 'Vildagliptin delayed' on Facebook Share 'Vildagliptin delayed' on Google+ Share 'Vildagliptin delayed' on reddit Share 'Vildagliptin delayed' on StumbleUpon Share 'Vildagliptin delayed' on Twitter

atomic-wealth

One Comments to “Vildagliptin delayed”

  1. [...] This provides some reassurance with respect to the liver enzyme elevations that delayed the drugs launch however patients with clinically significant liver disease or abnormal liver enzyme results at [...]

    Pingback by Prescribing Advice For GPs » Longer Term Gliptin Data — May 22, 2009 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,430 spam comments.

atomic-wealth
fond-illness
summer